Requires the commissioner of health to include in annual reports information regarding the cost and increase in cost of the ten prescription drugs on which the state expends the most money and which have had certain costs increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year.
Summary
Bill A00115 amends the public health law to require the New York State Commissioner of Health to include specific information in annual reports regarding prescription drug costs. The bill mandates that the commissioner, in consultation with the drug utilization review board, identify the ten prescription drugs that the state spends the most money on, focusing on those that have seen significant price increases. This includes drugs whose wholesale acquisition costs have increased by 50% or more over the past five years or by 10% or more during the previous calendar year. The report must detail the percentage increase in cost, total state expenditure for each drug, and additional information from manufacturers regarding the factors contributing to cost increases.
Impact
The bill aims to enhance transparency in prescription drug pricing and could lead to more informed decision-making by the state regarding its pharmaceutical expenditures. By requiring detailed reporting on drug costs and the factors contributing to price increases, it may influence future negotiations and policies related to drug pricing and reimbursement. This could potentially lead to legislative changes aimed at controlling drug costs and improving access to medications for residents.
Sentiment
The sentiment around Bill A00115 appears to be generally supportive among health advocates who emphasize the need for transparency in drug pricing. However, there may be concerns from pharmaceutical manufacturers regarding the requirement to disclose detailed financial information, which could be viewed as burdensome or intrusive. The lack of recorded votes or committee discussions suggests that the bill's reception is still being gauged.
Contention
Notable points of contention may arise from pharmaceutical companies who may oppose the requirement to disclose detailed financial data and explanations for price increases. Advocates for patients and consumers, on the other hand, are likely to support the bill as a necessary step toward accountability in drug pricing. The balance between transparency and the potential impact on drug manufacturers' business practices could be a significant area of debate.
Same As
Requires the commissioner of health to include in annual reports information regarding the cost and increase in cost of the ten prescription drugs on which the state expends the most money and which have had certain costs increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year.
Requires the commissioner of health to include in annual reports information regarding the cost and increase in cost of the ten prescription drugs on which the state expends the most money and which have had certain costs increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year.
Requires the commissioner of health to include in annual reports information regarding the cost and increase in cost of the ten prescription drugs on which the state expends the most money and which have had certain costs increased by fifty percent or more over the past five years or by ten percent or more during the previous calendar year.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provides the list to the attorney general to obtain reasons for the cost increases.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
Defines the types of capital improvement costs pursuant to which a manufactured home park may increase rent above three percent over the previous rent price.
Prohibits the termination of tenancy in housing occupied by substantially all persons over sixty-five years of age and/or persons with disabilities without cause; prohibits increasing rent more than one percent above the percentage change.
Prohibits the termination of tenancy in housing occupied by substantially all persons over sixty-five years of age and/or persons with disabilities without cause; prohibits increasing rent more than one percent above the percentage change.